Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study

BACKGROUND: Previous studies have shown left-sided colorectal cancer (LCRC) and right-sided colorectal cancer (RCRC) exhibit different molecular and clinicopathological features. We explored the association between the primary tumor site and cetuximab efficacy in KRAS wild-type colorectal cancer (CR...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Chen, Kuo-Hsing, Shao, Yu-Yun, Chen, Ho-Min, Lin, Yu-Lin, Lin, Zhong-Zhe, Lai, Mei-Shu, Cheng, Ann-Lii, Yeh, Kun-Huei
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879738/
https://ncbi.nlm.nih.gov/pubmed/27221731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2358-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars